H. D. Seth, S. Sultan, and M. H. Gotfried, Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease, J Thorac Dis, vol.5, issue.6, pp.806-820, 2013.

, Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2016.

G. Boyd, A. H. Morice, J. C. Pounsford, M. Siebert, N. Peslis et al., An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD), Eur Respir J, vol.10, issue.4, pp.815-836, 1997.

M. Cazzola, M. G. Matera, G. Santangelo, A. Vinciguerra, F. Rossi et al., Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study, Respir Med, vol.89, issue.5, pp.357-62, 1995.

A. Rossi, P. Kristufek, B. E. Levine, M. H. Thomson, D. Till et al., Formoterol in Chronic Obstructive Pulmonary Disease IISG. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of, COPD. Chest, vol.121, issue.4, pp.1058-69, 2002.

C. S. Ulrik, Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study, Thorax, vol.50, issue.7, pp.750-754, 1995.

P. Albert, A. Agusti, L. Edwards, R. Tal-singer, J. Yates et al., Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease, Thorax, vol.67, issue.8, pp.701-709, 2012.

M. Molimard, J. Bourcereau, L. Gros, V. Bourdeix, and I. , Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD, Respir Med, vol.99, issue.6, pp.695-702, 2005.

, Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2014.

B. R. Celli, W. Macnee, A. Agusti, A. Anzueto, B. Berg et al., Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper, Eur Respir J, vol.23, pp.932-946, 2004.

R. Pellegrino, G. Viegi, V. Brusasco, R. O. Crapo, F. Burgos et al., Interpretative strategies for lung function tests, Eur Respir J, vol.26, issue.5, pp.948-68, 2005.

C. Pitzalis, G. W. Jones, M. Bombardieri, and S. A. Jones, Ectopic lymphoid-like structures in infection, cancer and autoimmunity, Nat Rev Immunol, vol.14, issue.7, pp.447-62, 2014.

S. S. Kon, D. Dilaver, M. Mittal, C. M. Nolan, A. L. Clark et al., The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference, Thorax, vol.69, issue.9, pp.793-801, 2014.

N. A. Hanania, A. Sharafkhaneh, B. Celli, M. Decramer, T. Lystig et al., Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial, Respir Res, vol.12, p.6, 2011.

D. Tashkin and S. Kesten, Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses, Chest, vol.123, issue.5, pp.1441-1450, 2003.

M. R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi et al., Standardisation of spirometry, Eur Respir J, vol.26, issue.2, pp.319-357, 2005.

P. Calverley, P. Albert, and P. P. Walker, Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. The Lancet Respiratory Medicine, vol.1, pp.564-73, 2013.

N. A. Hanania, B. R. Celli, J. F. Donohue, and U. J. Martin, Bronchodilator reversibility in COPD, Chest, vol.140, issue.4, pp.1055-63, 2011.

R. Pellegrino and V. Brusasco, Point: Is an increase in FEV (1) and/or FVC >/= 12% of control and >/= 200 mL the best way to assess positive bronchodilator response?, Yes. Chest, vol.146, issue.3, pp.536-543, 2014.

J. E. Hansen, J. Porszasz, and . Counterpoint, Is an increase in FEV (1) and/or FVC >/= 12% of control and >/= 200 mL the best way to assess positive bronchodilator response?, No. Chest, vol.146, issue.3, pp.538-579, 2014.

L. P. Mcgarvey, M. John, J. A. Anderson, M. Zvarich, R. A. Wise et al., Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee, Thorax, vol.62, issue.5, pp.411-416, 2007.

L. P. Mcgarvey, S. Magder, D. Burkhart, S. Kesten, D. Liu et al., Cause-specific mortality adjudication in the UPLIFT (R) COPD trial: findings and recommendations, Respir Med, vol.106, issue.4, pp.515-536, 2012.

O. Kornmann, R. Dahl, S. Centanni, A. Dogra, R. Owen et al., Inlight-study investigators: Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison, Eur Respir J, vol.37, issue.2, pp.273-282, 2011.

R. Buhl, L. J. Dunn, C. Disdier, C. Lassen, C. Amos et al., Intensity study investigators: Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD, Eur Respir J, vol.38, issue.4, pp.797-803, 2011.

W. D. Van-dijk, N. Gupta, W. C. Tan, and J. Bourbeau, Clinical relevance of diagnosing COPD by fixed ratio or lower limit of normal: a systematic review, Copd, vol.11, issue.1, pp.113-133, 2014.